Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets
Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets
复制标题
部分脱硫肝素调节抗鱼精蛋白/肝素抗体与血小板之间的相互作用
DOI:
10.1160/th15-07-0539
复制
发表时间:
2015
影响因子:
6.7
通讯作者:
Bakchoul T
中科院分区:
文献类型:
--
作者:
Jouni R;Zollner H;Khadour A;Wesche J;Delcea M;Krauel K;Schwertz H;Sachs UJ;Greinacher A;Bakchoul T
Protamine (PRT) is the standard drug to neutralise heparin. PRT/heparin complexes induce an immune response similar to that observed in heparin-induced thrombocytopenia (HIT). Partially desulfated heparin (ODSH) was shown to interfere with anti-platelet factor 4/heparin antibodies (Abs), which are responsible for HIT. In this study, we analyse the impact of ODSH on the interaction between anti-PRT/heparin Abs and platelets. The ability of ODSH to prevent anti-PRT/heparin Ab-induced platelet destructionin vivowas investigated using the NOD/ SCID mouse model. ODSH improved platelet survival in the presence of PRT, heparin and anti-PRT/heparin Abs (median platelet survival after 300 minutes (min) with 20 μg/ml ODSH: 75 %, range 70–81 % vs without ODSH: 49%, range 44–59%, p=0.006). Furthermore, when ODSH was applied 60 min after Ab injection platelet survival was improved (median platelet survival after 300 min with ODSH: 83 %, range 77–93 % vs without ODSH: 59 %, range 29–61 %, p=0.02). Inin vitroexperiments ODSH inhibited platelet activation at concentrations > 16 μg/mL (p< 0.001), as well as PRT/heparin complex binding to platelets (mean fluorescence intensity [MFI] without ODSH: 85 ± 14 vs with ODSH: 15 ± 0.6, p=0.013). ODSH also displaced pre-bound complexes from the platelet surface (MFI without ODSH: 324 ± 43 vs with 32 μg/ml ODSH: 53 ± 9, p< 0.001). While interfering with platelet activation by anti-PRT/heparin Abs, up to a concentration of 16 μg/ml, ODSH had only minimal impact on neutralisation of heparin by PRT. In conclusion, our study shows that ODSH is able to inhibit platelet activation and destruction suggesting a potential clinical use to reduce anti-PRT/heparin Ab-mediated adverse effects.
登录
查看更多内容
影响因子:
5.5
作者:
Rao, Narayanam V.;Argyle, Brian;Kennedy, Thomas P.
通讯作者:
Kennedy, Thomas P.
影响因子:
6.7
作者:
Joglekar MV;Quintana Diez PM;Marcus S;Qi R;Espinasse B;Wiesner MR;Pempe E;Liu J;Monroe DM;Arepally GM
通讯作者:
Arepally GM
DOI:
10.1515/cclm-2014-0664
发表时间:
2015
期刊:
Clinical Chemistry and Laboratory Medicine (CCLM)
影响因子:
--
作者:
S. Panzer;A. Schiferer;B. Steinlechner;L. Drouet;J. Amiral
通讯作者:
J. Amiral
影响因子:
20.3
作者:
Bakchoul, Tamam;Zoellner, Heike;Greinacher, Andreas
通讯作者:
Greinacher, Andreas
影响因子:
4.6
作者:
Butterworth, J;Lin, YA;James, RL
通讯作者:
James, RL